Humanitarian use devices huds and humanitarian device exemption hdes
Download
1 / 15

Humanitarian Use Devices HUDs and Humanitarian Device Exemption - HDEs - PowerPoint PPT Presentation


  • 615 Views
  • Uploaded on

Humanitarian Use Devices – HUDs and Humanitarian Device Exemption - HDEs. National Institutes of Health Product Life Cycle of an Investigational Device Exemption. Eric Chen Director Humanitarian Use Devices Designation Program Office of Orphan Products Development

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about 'Humanitarian Use Devices HUDs and Humanitarian Device Exemption - HDEs' - Rita


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
Humanitarian use devices huds and humanitarian device exemption hdes l.jpg

Humanitarian Use Devices – HUDs and Humanitarian Device Exemption - HDEs

National Institutes of HealthProduct Life Cycle of anInvestigational Device Exemption

Eric Chen

Director

Humanitarian Use Devices Designation Program

Office of Orphan Products Development

Food and Drug Administration

June 24, 2010


Intent of hde provision l.jpg
Intent of HDE Provision Exemption - HDEs

Provide incentive for development of

devices intended for treatment or

diagnosis, in small patient populations

where otherwise a device

manufacturer’s R&D costs would

exceed market returns

NIH


Section 520 m of the food drug and cosmetic act l.jpg
Section 520(m) of the Food, Drug and Cosmetic Act Exemption - HDEs

“… to encourage the discovery and use of devices intended to benefit patients in the treatment and diagnosis of diseases or conditions that affect fewer than 4,000 individuals in the United States.” [yearly]

NIH


Statutory conditions l.jpg
Statutory Conditions Exemption - HDEs

  • Device not otherwise available

  • No comparable device available

  • Device:

    • Does not pose unreasonable risk of illness or injury [i.e., safety], AND

    • Probable benefit outweighs the risk (i.e., exempt from effectiveness requirements of a PMA)

NIH


Statutory conditions5 l.jpg
Statutory Conditions Exemption - HDEs

  • Approval authorizes marketing of HUD

  • IRB approval required before device used

  • Local IRB may approve or defer

  • Labeling must clearly identify device as HUD, and that effectiveness for that indication has not been demonstrated

  • Amount charged cannot exceed cost of research, development, manufacturing and distribution

    • Pediatric HUDs can make a profit (FDAAA)

NIH


Statute to regulation l.jpg
Statute to Regulation Exemption - HDEs

  • Post-Safe Medical Devices Act (SMDA) of 1990, proposed rule based on modified IDE regulation

  • Final rule June 1996 - new subpart H added to existing PMA regulation (21 CFR 814)

  • Effective October 1996

  • Modified by Food and Drug Modernization Act (FDAMA) November 1997

NIH


21 cfr 814 subpart h l.jpg
21 CFR 814 Subpart H Exemption - HDEs

  • Modeled after PMA regulation

    • Submission format similar to PMA

    • Amendments/supplements

    • Annual reports

    • GMP/MDR requirements

  • Approval thresholds differ:

    • PMA: safety and effectiveness

    • HDE: safety and probable benefit

      • No regulatory definition of probable benefit but we encourage sponsors to work with FDA to develop an appropriate level of benefit for their device

NIH


Hud designation by oopd 21 cfr 814 subpart h l.jpg
HUD Designation by OOPD Exemption - HDEs(21 CFR 814 Subpart H)

Part 1 of the two part review/approval process:

  • Request submitted to FDA’s Office of Orphan Products Development (not CDRH)

  • Designates the intended population for the device

    • Incidence must be < 4000/year in the U.S.

    • If subset of a larger population, must be “medically plausible” subset

  • 45 day review

NIH


Medically plausible subset l.jpg
“Medically Plausible Subset” Exemption - HDEs

If the disease or conditions occurs in >4,000 pts./yr., the device could be used in a subset of the disease or condition AS LONG AS the sponsor shows the subset is medically plausible (NOT just "readily identifiable“). A medically plausible subset is one in which use of the device is limited to that subset because of some inherent property of the device and/or the disease. That is, the sponsor must explain why the device couldn't also be used in all pts. with disease or condition.

NIH


Hde review by cdrh l.jpg
HDE review by CDRH Exemption - HDEs

Part 2 of the two part review/approval process must include the following:

  • HUD designation (granted by Office of Orphan Products)

  • Explanation why device would not otherwise be available

  • Statement that no comparable device exists

  • Device description

    Approved indications for use may be narrower than HUD designation

NIH


Hde review by cdrh con t l.jpg
HDE review by CDRH con’t Exemption - HDEs

  • Preclinical information

  • Clinical experience: data, literature, OUS, data gained from same device in different patient population

    • Clinical trials are usually not randomized or controlled due to small sample size and lack of a comparable marketed device

    • Clinical trial data is help to describe device performance and adverse events

    • Clinical trial data may clearly define patient population and patient management protocols

NIH


Hde review by cdrh con t12 l.jpg
HDE review by CDRH con’t. Exemption - HDEs

  • Manufacturing information: Quality Systems Regulation (QSR) applies (unless elements waived)

  • Labeling (physician and patient), including HUD statement (that no effectiveness demonstrated)

NIH


Key points l.jpg
Key Points Exemption - HDEs

  • HDE is marketing approval

  • Exempt from effectiveness requirements but not safety requirement

  • IRB approval required

  • Informed Consent not required by FDA

  • No requirement to submit PMA/510(k)

  • Can have multiple HDEs for same indication from different sponsors

NIH


Slide14 l.jpg

Since 1996 Exemption - HDEs

  • 50 approved HDEs

  • 155 designated HUDs

  • 239 submitted HUD applications

  • List of approved HDEs and their Summaries of Safety and Probable Benefit (SSPB) available at:

    http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/DeviceApprovalsandClearances/HDEApprovals/ucm161827.htm

NIH


Thank you l.jpg
Thank you Exemption - HDEs

  • Contact information:

    Sheila Brown – IDE/HDE staff

    (301) 796-6563

    [email protected]

    Lynn Henley – IDE/HDE staff

    (301) 796-6120

    [email protected]

    Eric Chen – Director of HUD Program, OOPD

    (301) 796-6327

    [email protected]

NIH


ad